Knte News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Knte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Knte Today - Breaking & Trending Today

Acuitas Investments LLC Invests $687,000 in Kinnate Biopharma Inc. (NASDAQ:KNTE)

Acuitas Investments LLC purchased a new position in Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 289,766 shares of the company’s stock, valued at approximately $687,000. Acuitas Investments LLC owned approximately 0.62% of Kinnate Biopharma […] ....

United States , William Blair , Kinnate Biopharma , Stifel Nicolaus , Citigroup Inc , Capital Management , Acadian Asset Management , Acuitas Investments , Kinnate Biopharma Inc , Connor Clark Lunn Investment Management Ltd , Free Report , Fire Capital , Lunn Investment Management , Asset Management , Biopharma Inc , Cyclin Dependent Kinase , Visit Holdingschannel , Kinnate Biopharma Daily , Nasdaq Knte , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Pale Fire Capital SE Raises Position in Kinnate Biopharma Inc. (NASDAQ:KNTE)

Pale Fire Capital SE raised its stake in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) by 196.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,174 shares of the company’s stock after acquiring an additional 46,492 shares during the quarter. Pale […] ....

United States , Kinnate Biopharma , William Blair , Metlife Investment Management , Kinnate Biopharma Inc , Jpmorgan Chase Co , Blackrock Inc , Exchange Commission , Pale Fire Capital , Free Report , Fire Capital , Life Investment Management , Biopharma Inc , Cyclin Dependent Kinase , Visit Holdingschannel , Kinnate Biopharma Daily , Nasdaq Knte , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Kinnate Biopharma Inc. (NASDAQ:KNTE) Receives Consensus Rating of "Hold" from Brokerages

Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Free Report) has earned a consensus rating of “Hold” from the five brokerages that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among […] ....

United States , Kinnate Biopharma , Tower Research Capital , Kinnate Biopharma Inc , Principal Financial Group Inc , Kinnate Biopharma Company Profile , Get Free Report , Marketbeat Ratings , Research Capital , Principal Financial Group , Get Free , Biopharma Inc , Cyclin Dependent Kinase , Kinnate Biopharma Daily , Nasdaq Knte ,